UHealth - University of Miami Health System

E-mail a Friend

Jaime R. Merchan, M.D.

General Information

Jaime R. Merchan, M.D.


  • Fax: 305-243-9161


  • Internal Medicine
  • Hematology/Oncology - Internal Medicine
  • Medical Oncology - Internal Medicine


English, Spanish, German, Portuguese

Clinical Areas

Kidney Cancer
Bladder Cancer
Prostate Cancer

Video Introduction


  • American Board of Internal Med-Hematology
  • American Board of Internal Med-Medical Oncology


  • Associate Professor of Medicine Director, Phase 1 Clinical Trials Program

Research Interests

Experimental Therapeutics; Phase 1 Clinical Trials

Tumor Angiogenesis, Vascular Targeting, Oncolytic Virotherapy


  • Merchan J: Chemotherapy and Renal Insufficiency. In: UpToDate, Rose, BD (Ed), Waltham, MA, 2013.
  • Cudris Maldonado J, Merchan J. Immunotherapy in Renal Cell Carcinoma, in Advances in Tumor Immunology and Immunotherapy. J.D. Rosenblatt, E.R. Podack, G.N.Barber, A. Ochoa (Eds). 125-147. 2013.
  • Merchan JR., The Oncologist and Renal Cell Carcinoma, In: Incidental Finding, C. Chauhan and M. Blute (Eds). 39-44, 2007
  • Soares H, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green M, Silva O, Levi J, Walker G, Rocha-Lima C. A Phase II Study of Capecitabine Plus Docetaxel in Gemcitabine-refractory Metastatic Pancreatic Cancer Patients: CapTere. Cancer Chemotherapy and Pharmacology (Accepted for publication, 2014).
  • Y Jing, J Zaias, R Duncan, SJ Russell and JR Merchan. In Vivo Safety, Biodistribution And Antitumor Effects Of uPAR Retargeted Oncolytic Measles Virus In Syngeneic Cancer Models. Gene Therapy advance online publication 16 January 2014; doi: 10.1038/gt.2013.84.
  • Palacio S, Loaiza-Bonilla A, Kittaneh M, Kyriakopoulos C, Ochoa RE, Escobar M, Arango B, Restrepo MH, Merchan JR, Lima CM, Hosein PJ. Successful Use of Trastuzumab with Anthracycline-based Chemotherapy Followed by Trastuzumab Maintenance in Patients with Advanced HER2-positive Gastric Cancer. Anticancer Res. 2014 Jan;34(1):301-6. PubMed PMID: 24403478.
  • Kurisetti V, Heiber J, Myers R, Pereira GS, Goodwin JW, Federspiel MJ, Russell SJ, Peng KW, Barber G, Merchan JR. Preclinical Safety And Activity of VSV-IFN-ß In An Immunocompetent Model Of Squamous Cell Carcinoma of The Head And Neck. Head Neck. 2013 Sep 30. doi: 10.1002/hed.23502. [Epub ahead of print] PubMed PMID: 24115092.
  • Motzer RJ, Hudson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, deSouza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Hammenbard U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, CrescenzoR, Pandite LN, Choueri TK. Pazopanib Versus Sunitinib in Metastatic Renal Cell Carcinoma. N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989. PubMed PMID: 23964934
  • Xi H, Barredo JC, Merchan JR, Lampidis TJ. Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKß leading to autophagy. Biochem Pharmacol. 2013 May 15;85(10):1463-77. doi: 10.1016/j.bcp.2013.02.037. Epub 2013 Mar 13. PubMed PMID: 23500541
  • Wang X, Li G, Wang A, Zhang Z, Merchan JR, Halmos B. Combined Histone Deacetylase and Cyclooxygenase Inhibition Achieves Enhanced Antiangiogenic Effects in Lung Cancer Cells. Mol Carcinog. 2013 Mar;52(3):218-28. doi: 10.1002/mc.21846. Epub 2011 Nov 28. PubMed PMID: 22121107
  • Jing J, Kovacs, K, Kurisetti V, Jiang Z, Tsinoremas N, Merchan J.R. Role Of Plasminogen Activator Inhibitor-1 In Urokinase’s Paradoxical In Vivo Tumor Suppressing Or Promoting Effects. Mol Cancer Res. 2012 Oct; 10(10):1271-81. PubMed Central PMCID: PMC3495620.
  • Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012 May 29;12:199. doi: 10.1186/1471-2407-12-199. PubMed PMID: 22642850; PubMed Central PMCID: PMC3404979
  • Hosein PJ, Lopes Jr GD, Pastorini VH, Gomez CM, Macintyre J, Zayas G, Reis IM, Montero AJ, Merchan JR, Rocha Lima CM. A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol. 2013 Apr;36(2):151-6. doi: 10.1097/COC.0b013e3182436e8c. PubMed PMID: 22307213.
  • Isham CR, Tibodeau JD, Bossou AR, Merchan JR, Bible KC. The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation. BMC Cancer. 2012 May 29;12:199. doi: 10.1186/1471-2407-12-199. PubMed PMID: 22642850; PubMed Central PMCID: PMC3404979.
  • Kubiliun N, Ribeiro A, Fan YS, Rocha-Lima CM, Sleeman D, Merchan J, Barkin J, Levi J. EUS-FNA with rescue Fluorescence in situ hybridization for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results. Gastrointest Endosc. 2011 Sep;74(3):541-7. doi: 10.1016/j.gie.2011.04.043. Epub 2011 Jul 12. PubMed PMID: 21752364.
  • JR Merchan, A Venkatraman, J Macintyre, KK Ciombor, J Levi, A Ribeiro, D Sleeman, A. Flores, M. Vulfovich, CM Rocha-Lima. Phase 2 study of Gemcitabine (g), oxaliplatin (o), cetuximab (c) for locally advanced or metastatic pancreatic cancer. Am J Clin Oncol. 2012 Oct;35(5):446-50. PubMed PMID: 21552097
  • Shin S-U, Cho H-M, Merchan J, Zhang J, Kovacs K, Jing Y, Ramakrishnan S, and Rosenblatt JD. Targeted delivery of anti-HER2 antibody-human endostatin P125A mutant fusion protein results in enhanced anti-tumor efficacy in murine and human breast tumor models. Mol Cancer Ther. 2011 Apr;10(4):603-14. doi: 10.1158/1535-7163.MCT-10-0804. Epub 2011 Mar 10. PubMed PMID: 21393427.
  • Ascunce G, Ribeiro A, Reis I, Rocha-Lima C, Sleeman D, Merchan J, Levi J. EUS visualization and direct celiac ganglia neurolysis predicts better pain relief in patients with pancreatic malignancy (with video). Gastrointest Endosc. 2011 Feb;73(2):267-74. doi: 10.1016/j.gie.2010.10.029. PubMed PMID: 21295640
  • Houston SK, Pina Y, Murray TG, Boutrid H, Cebulla C, Schelfler AC, Shi W, Celdran M, Feuer W, Merchan J, Lampidis TJ. Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LHBETATAG retinoblastoma tumors. 2011. Clinical Ophtalmology. 2011 Jan 27; 5:129-37. doi: 10.2147/OPTH. S15179. PubMed PMID: 21339806; PubMed Central PMCID: PMC3037041
  • Merchan JR, Kovacs K, Railsback JW, Kurtoglu M, Jing Y, Pina Y, Murray TG, Lehrman MA, Lampidis TJ. Antiangiogenic Activity of 2-deoxy-D-glucose (2-DG). PLoS One. 2010 Oct 27;5(10):e13699. doi: 10.1371/journal.pone.0013699. PubMed PMID: 21060881; PubMed Central PMCID: PMC2965179.
  • Talebi, TN, Stefanovic, A, Merchan J, Lian E, Silva, O. Sunitinib-induced Microangiopathic Hemolytic Anemia with Fatal Outcome. American Journal of Therapeutics. 27 August 2010. 10.1097/MJT.0b013e3181eefe8b. PubMed PMID: 21403468.
  • R.S. Bhatt, J. Merchan, R. Parker, H. Wu, L. Zhang, V. Seery, J.V Heymach, M.B. Atkins, D. McDermott, V.P. Sukhatme. A phase II pilot trial of low dose, continuous infusion, or “metronomic”, paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer, 2010. 116 (7): 1751 – 1756. doi: 10.1002/ cncr.24902. PubMed PMID: 20120033; PubMed Central PMCID: PMC2847062.
  • Ascunce G, Ribeiro A, Rocha-Lima C, Larsen, M, Sleeman D, Merchan J, Szabo D, Levi J. Single Session EUS/ERCP in the evaluation of pancreaticobiliary disorders. Surgical Endoscop, 2010 Jun;24(6):1447-50. Epub 2010 Jan 7. PubMed PMID: 20054580.
  • Yuqi Jing, Caili Tong, Jin Zhang, Takafumi Nakamura, Ianko Iankov, Stephen J. Russell, Jaime R. Merchan. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Research, 2009 Feb 15; 69(4):1459-1468. doi: 10.1158/0008-5472.CAN-08-2628. Epub 2009 Feb 10. PubMed PMID: 19208845; PubMed Central PMCID: PMC2739455
  • G Huang, R Eisenberg, M Yan, S Monti, E Lawrence, P Fu, J Walbroehl, E Löwenberg, T Golub, J Merchan, D Tenen, S Markowitz, B Halmos. 15-hydroxyprostaglandin dehydrogenase is a target of HNF3ß and a tumor suppressor in lung cancer. Cancer Research, 2008 Jul 1;68(13):5040-8. doi: 10.1158/0008-5472.CAN-07-6575. PubMed PMID: 18593902; PubMed Central PMCID: PMC2762106.
  • Markovic SN, Suman VJ, Rao RA, Ingle J, Kaur J S., Erickson LA., Pitot HC., Croghan GA, Merchan J R., Kottschade L., Nevala WK., Uhl CB., Alfred J., Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. American Journal of Clinical Oncology. 2007 Jun;30(3):303-9. PubMed PMID: 17551310.
  • Merchan J, Tang J, Hu G, Lin Y, Mutter W, Karumanchi S, Sukhatme V. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. Journal of the National Cancer Institute 2006; 98(11): 756-64. Editorial by Masashi Narazaki and Giovanna Tosato: J Natl Cancer Inst 2006 98: 726-727. PubMed PMID: 16757700.
  • Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding GT, Ginsberg MS, Bacik J, Bello CL, Kim ST, Baum CM, Michaelson MD: Pivotal Study of Sunitinib Malate (SU11248) Shows Efficacy in Patients with Metastatic Renal Cell Carcinoma. Journal of the American Medical Association 2006: 2516-24. PubMed PMID: 16757724.
  • Leibovich BC, Cheville JC, Lohse CM, Zincke H, Kwon ED, Merchan JR, Blute ML: A Scoring Algorithm to Predict Survival for Patients with Metastatic Renal Cell Carcinoma: Stratification Tool for Prospective Clinical Trials. J Urol. 2005 Nov; 174(5):1759-63. discussion 1763. PubMed PMID: 16217278.
  • Hallak, L.K ; Merchan, J; Storgard, C.; Loftus, J; Russell, S.J. Tumor regression after treatment with targeted measles virus displaying echistatin against proliferating endothelial cells and multiple myeloma model tumors. Cancer Res. 2005 Jun 15; 65(12):5292-300. PubMed PMID: 15958576.
  • Merchan J, Jayaram D, Supko J, He X, Bubley G, Sukhatme V: Increased Endothelial Uptake Of Paclitaxel As A Potential Mechanism For Its Antiangiogenic Effects: Potentiation By Cox-2 Inhibition. International Journal of Cancer.2005 Jan 20;113(3):490-8. PubMed PMID: 15455390
  • Chan B*, Merchan J*, Kale S, Sukhatme V: Antiangiogenic Property of Human Thrombin. Microvascular Research. Microvasc Res. 2003; 66(1):1-14. *Shared first authorship. PubMed PMID: 12826069
  • Maynard SE, Min J, Merchan J, Lim KH, Li J, Mondal S, Libermann T, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukatme VP, Karumanchi SA: Excess placental sFlt-1 contributes to endothelial dysfunction, hypertension and proteinuria of pre-eclampsia. J. Clin. Invest. 2003 111: 649-658. PubMed PMID: 12618519; PubMed Central PMCID: PMC151901. Editorial by Aernout Luttun and Peter Carmeliet. J. Clin. Invest. 2003 111: 600-602.
  • Merchan J, Chan B, Kale S, Schnipper L, Sukhatme V: In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril J Natl Cancer Inst 2003; 95: 388-399. PubMed PMID: 12618504.
  • Karumanchi SA, Merchan J, Sukhatme VP: Renal Cancer –Molecular mechanisms and newer therapeutic options. Current Opinions in Nephrology and Hypertension. 2002, 11: 37-42. PubMed PMID: 11753085.
  • Ardalan B, Raez L, Merchan J, Franceschi D, et al.: Biomodulation of Fluorouracil in Colorectal Cancer. Cancer Invest; 16(4): 237-51 1998.
  • Freire A, Cely C, Merchan J.: Spontaneous Pneumothorax and Cancer: Report of three cases and Review of the Literature. Oncologia. 1994; 2: 13-16.


BFBCI Bankhead Coley Breast Cancer SPORE planning grant career development award
Stanley J. Glaser Research Award
American Association of Cancer Research Database of Exceptional Minority Scientists
Susan G. Komen Breast Cancer Foundation Award
Eagles Pilot Award
Pfizer Fellowship in the Clinical Investigator Training Program
American Society of Clinical Oncology Young Investigator Award
Chief Medical Resident, University of Miami School of Medicine
Catholic University School of Medicine Award for the Best Doctoral Thesis
Recognition Diplomas for Academic Excellence during Medical School


2003 Masters
Harvard Medical School and Massachusetts Institute of Technology
1998 Fellowship
Beth Israel Deaconess Med Ctr/Harvard Medical School
1997 Chief Resident
U of Miami/VA Medical Center
1995 Residency
U of Miami/Jackson Memorial Med Center
1994 Internship
U of Miami/Jackson Memorial Med Ctr
1992 M.D.
Universidad Catolica de Santiago de Guayaquil


E-mail a Friend